"Mid Atlantic Retina is an internationally recognized, pre-eminent retina practice in Pennsylvania, New Jersey and Delaware delivering state-of-the-art, comprehensive patient care for over 40 years. Our retina specialists are world-renowned and board-certified physicians with over 400 years of combined expertise. They are recognized as leaders in vitreoretinal diseases by ophthalmology and medical societies. We are dedicated to the diagnosis and treatment of retina, vitreous and macula disorders, with the goal of restoring and maintaining sight to improve the quality of life for our patients. See a Wills Eye Doctor in Philadelphia today."

During the past decade, Mid Atlantic Retina / Wills Eye Institute conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 5 clinical trials were completed, i.e. on average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mid Atlantic Retina / Wills Eye Institute" #1 sponsor was "Wills Eye" with 7 trials, followed by "Astellas Institute for Regenerative Medicine" with 4 trials sponsored, "MidAtlantic Retina" with 2 trials sponsored, "Jason Hsu, MD" with 1 trials sponsored and "Julia Haller" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mid Atlantic Retina / Wills Eye Institute" #1 collaborator was "Mid Atlantic Retina" with 4 trials as a collaborator, "J. Arch McNamara Research Fund" with 1 trials as a collaborator, "MEDARVA Foundation" with 1 trials as a collaborator, "National Center for Complementary and Integrative Health (NCCIH)" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Mid Atlantic Retina / Wills Eye Institute" are "Age-Related Macular Degeneration" (2 trials), "Age-related Macular Degeneration" (2 trials), "Macular Degeneration" (2 trials), "Stargardt's Macular Dystrophy" (2 trials) and "Wet Macular Degeneration" (2 trials). Many other conditions were trialed in "Mid Atlantic Retina / Wills Eye Institute" in a lesser frequency.

Most popular intervention types in "Mid Atlantic Retina / Wills Eye Institute" are "Drug" (7 trials), "Biological" (5 trials), "Device" (2 trials), "Dietary Supplement" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "MA09-hRPE" (4 trials), "Dorzolamide-timolol" (2 trials), "27-gauge vitrectomy wound construction" (1 trials), "Artificial tears" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mid Atlantic Retina / Wills Eye Institute" are 18 trials for "All" genders.

Currently, there are NaN active trials in "Mid Atlantic Retina / Wills Eye Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Mid Atlantic Retina / Wills Eye Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Mid Atlantic Retina / Wills Eye Institute, 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".